Better Data on Ivermectin Is Finally on Its Way
Studies have been small and often not great. The best info so far says don’t use it, get vaccinated, and hang in there for the more promising meds being tested.
今日の英語の習慣化の題材は..
Corona 関連のお薬のお話です。
Covidに効果が認められたIvermectin(イベルネクティン)などの通常の薬と使用可能性が高まります。
医学用語が多少難しいですが、日本語でカタカナ医学用語を英語で知っておくのも知識のうちですので頑張ってみましょう!
なお英単語には、認知単語(読めて知っておくだけで良い単語)と能動単語(自分が使える単語)が有りますので気にしないでイメージ的に記憶してみましょう!
EDWARD MILLS CAME to the meeting last month with very good data. A clinical trials expert at McMaster University, Mills was presenting new results from a trial that is looking at how well half a dozen different drugs treat Covid-19—not for the people so sick they’re in the emergency room or the hospital, but in people whose symptoms haven’t gotten that bad yet. People sick at home, in other words.
At his online talk, put on by the National Institutes of Health, Mills’ slides told the tale: A relatively safe, familiar, cheap drug reduced the relative risk of mild Covid getting worse by nearly 30 percent. The drug is fluvoxamine, a selective serotonin reuptake inhibitor—an antidepressant. (It’s also an anti-inflammatory, and inflammation and an overreacting immune system are hallmarks of serious Covid infection, so that might be why it seems to help). Get a bunch of people with Covid and randomize them into two groups; 739 get fluvoxamine and 733 get a placebo. Only 77 of the fluvoxamine-takers end up in the hospital; 109 of the placebo group do. This is exciting.